Loading
A phase 2 trial of ABSK043 in combination with Firmonertinib in non-small-cell lung cancer, run by Abbisko Therapeutics Co, Ltd, now recruiting.
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib is a phase 2 interventional study registered as NCT06668103 by Abbisko Therapeutics Co, Ltd, with 54 participants planned, started 2024-11-25 and due to reach its primary completion in 2027-12-30. Interventions recorded: ABSK043 in combination with Firmonertinib.
Shares Abbisko Therapeutics and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Abbisko Therapeutics and the tag pipeline.
Shares Abbisko Therapeutics and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.